CO27 Real-World Treatment Response and Persistence Among Black and Non-Black Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide in a Urology Setting

B Lowentritt,S Du,C Rossi,F Kinkead,B Moore,P Lefebvre,D Pilon,E Muser,I Khilfeh

doi:10.1016/j.jval.2023.03.101

CO27 Real-World Treatment Response and Persistence Among Black and Non-Black Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide in a Urology Setting

B Lowentritt, S Du + Show 7 more

https://doi.org/10.1016/j.jval.2023.03.101

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Publication Date: Jun 1, 2023

Affiliation: Chesapeake Urology Associates, Janssen (United States)

#Treatment Persistence #Metastatic Castration-Sensitive Prostate Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the United States, real-world evidence on apalutamide (APA) for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) is limited. This study describes prostate-specific antigen (PSA) response and treatment persistence among patients with mCSPC initiated on APA, with stratifications for Black/non-Black patients.

Full Text